Overview
JW THERAP-B (2126)
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunot...
- Open
- 3.095
- High
- 3.095
- Low
- 2.420
- Prev. Close
- 2.695
- Volume
- 9.32M
- Turnover
- 25.67M
- Avg Price
- 2.753
- Bid/Ask Ratio
- 50.00%
- Amplitude
- 25.05%
- 52wk High
- 3.710
- Volume Ratio
- 16.13
- Turnover Ratio
- 2.24%
- 52wk Low
- 1.400
- HK Mkt Cap
- 1.04B
- Market CapHKD
- 1.04B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.935
- EPSDynamic
- -0.279
- EPSStatic
- --
- BVPS
- 1.25
- P/B
- 2.00
- HK Shares
- 416.88M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 416.88M
- Min lot size
- 500
- Currency
- HKD
JW THERAP-B Analyst Rating
View moreForecast & Rating
Sep 3, 2025- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
JW Therapeutics opened at HK$3.095 and sold off from an early HK$3.035 print at 09:39 BJ to HK$2.420 at 11:06 BJ, closing at HK$2.490, down 7.6% from HK$2.695 on 9.32 million shares and HK$25.66 million turnover, as the 13% move tied to Carteyva's 2026 NRDL inclusion and guidance for a more than 65% cut in unit manufacturing costs gave way to profit-taking. The operating trend still shows narrowing losses: Q2 2026 revenue rose 10.37% year on year to HK$64.31 million, net loss narrowed 80.11% to HK$29.12 million and EPS improved 80.16% to -HK$0.0699, though operating loss was HK$53.68 million. A HK$160 million placement and a US$10 million upfront payment from the Eureka licensed-asset transfer add financing and portfolio items. The close sits above MA20 of HK$2.45 and MA60 of HK$2.405, but remains 33.42% below the 52-week high of HK$3.74 and down 0.4% YTD. Though PB is 1.99 and market cap is HK$1.038 billion, the negative PE of -2.66 leaves valuation dependent on a future volume ramp.
- Nov, 13
JW Therapeutics-B staged a spike-and-fade session: the lift tied to its hepatocellular carcinoma TCR-T licensing deal stalled at an intraday high of HK$2.870 at 10:41 BJ, then slid to HK$2.675 at 15:19 and closed at HK$2.710, below the full-day average of HK$2.735 and 5.6% off the peak, on 2.819 million shares and a 0.67% turnover rate. That transaction transfers licensed assets to Eureka for a US$10 million upfront payment and had lifted the stock roughly 6% on the announcement, but after a 12.61% gain the prior week, profit-taking pressure around HK$2.87 was evident. Market capitalisation is HK$1.124 billion at a 2.16x price-to-book with a negative price-to-earnings ratio, consistent with continuing losses. Though, with turnover of only HK$7.71 million, the thin tape amplified the intraday swing.
- Nov, 12
JW Therapeutics (2126.HK) opened weak but climbed through the session and closed at HK$2.700, up 5.06%, after agreeing to transfer its licensed hepatocellular carcinoma TCR-T assets to Eureka for a US$10 million upfront payment. It dipped to HK$2.545 at 09:38 BJ, hit HK$2.775 at 14:11 BJ, then eased into the close on 2.229 million shares and HK$5.99 million turnover, a thin 0.53% turnover rate. The price sits above MA20 of HK$2.452 and MA60 of HK$2.379, up 8% year-to-date, yet remains 27.81% below the 52-week high of HK$3.74 (12 Nov 2025) and 92.86% above the HK$1.40 low of 21 June. Q2 2026 revenue was HK$64.3 million, up 10.37% year on year, while the net loss narrowed 80.11% to HK$29.1 million, leaving net margin at -45.28%, PB at 2.16 and PE negative. Though the US$10 million upfront is modest against a HK$1.126 billion market cap, and losses persist.
- Nov, 10
JW Therapeutics reversed an opening spike and regained ground, closing at HK$2.605 against a HK$2.505 prior close, up about 4.0%, after touching HK$2.675 at the 09:30 BJ open, sliding to HK$2.505 by 10:08 and recovering to HK$2.650 in the afternoon session on 882,500 shares. The trigger was the transfer of its liver-cancer TCR-T program rights to Eureka Hong Kong with a licence grant, bringing a US$10 million upfront payment while the company expects a US$2.1 million loss on disposal. Q2 2026 revenue was HK$64.3 million, up 10.37% year on year, and the net loss narrowed 80.11% to HK$29.1 million, though the net margin remains -45.28%. The stock sits above MA20 of HK$2.467 and MA60 of HK$2.355, up 4.2% year to date yet still 37.68% below the 52-week high of HK$4.18, with PB at 2.08x. Turnover rate was only 0.21%, while the disposal itself carries that US$2.1 million loss.
- Nov, 6
JW Therapeutics opened at HK$2.55 and faded, closing at HK$2.50 for a 6.02% decline on thin turnover of HK$1.35 million from 538,000 shares, a 0.13% turnover rate, with the pullback following gains of 6% and 12% in the prior two sessions. The morning session slid from a HK$2.595 high to HK$2.470 by 11:33, and an afternoon bounce to HK$2.570 faded into the close. Q2 2026 revenue was HK$64.31 million, up 10.37% year on year, and the net loss narrowed 80.11% to HK$29.12 million, though the net margin of -45.28% and ROE of -22.29% remain negative, alongside a 2.00x price-to-book and HK$1.04 billion market value. At HK$2.50 the stock sits on its 20-day average, flat year to date, 40.19% below the 52-week high of HK$4.18 while 78.57% above the HK$1.40 low. While CAR-T reimbursement inclusion and a recovering Hong Kong biotech licensing backdrop remain medium-term items to watch.
News
Yicai · JW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO Says
Market Movers · JW Therapeutics surges 13% as Carteyva added to NRDL
PUBT · JW Therapeutics Agrees to HKD 160 Million Private Share Placement
Tip Ranks · Carteyva Included in 2026 National Reimbursement Drug List
Tip Ranks · JW Therapeutics Plans Presentation on Carteyva® NRDL Inclusion
